Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Latisse

Latisse
In stock
3ml
from A$62.33
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$74.80A$62.33
A$62.33 per bottle

In brief

  • In Australia, Latisse (bimatoprost 0.03%) is generally a prescription medicine, but some local pharmacies and many online retailers/overseas suppliers offer Latisse or generic bimatoprost without requiring a prescription or receipt; availability and legality vary, and discreet delivery options are commonly advertised.
  • Latisse is used to promote eyelash growth (longer, thicker, darker lashes) and bimatoprost (the active ingredient) is a prostaglandin analogue that increases the anagen (growth) phase of eyelashes and, in ophthalmic use, lowers intraocular pressure by increasing aqueous humour outflow.
  • The usual dosage for eyelash enhancement is one drop of 0.03% solution applied to the base of the upper eyelashes once nightly; for glaucoma/ocular hypertension the standard is one drop in the affected eye(s) once daily (evening).
  • Form of administration: topical ophthalmic solution — applied with single-use applicators to the upper eyelid margin for lash enhancement, or as eye drops instilled into the conjunctival sac for intraocular pressure control.
  • Onset time: eyelash results generally begin to appear after about 8 weeks with fuller effects by 12–16 weeks; ocular pressure-lowering effects can begin within hours of dosing.
  • Duration of action: for glaucoma bimatoprost gives around 24-hour IOP control with once-daily dosing; for eyelash effects continued nightly use is required — stopping treatment leads to gradual reversal of lash changes over weeks to months.
  • Alcohol warning: there is no specific contraindication with moderate alcohol use, but avoid excessive alcohol if it increases eye irritation or dryness; always follow product instructions and seek medical advice if unsure.
  • The most common side effect is conjunctival hyperemia (eye redness); other frequent effects include eye irritation or itching, eyelid skin darkening and changes to eyelashes (growth and darkening); rare but important effects include increased iris pigmentation which may be permanent.
  • Would you like to try latisse without a prescription?

Basic Latisse Information

  • INN (International Nonproprietary Name): Bimatoprost is the INN for Careprost.
  • Brand Names Available In Australia: Brand names noted in the product data include Latisse (cosmetic eyelash growth), Lumigan (glaucoma/ocular hypertension) and Careprost (eyelash enhancement; 3 mL dropper vials are common internationally).
  • ATC Code: S01EE03 — ophthalmologicals, prostaglandin analogues, bimatoprost.
  • Forms & Dosages: Ophthalmic solution 0.03% w/v, commonly supplied in 3 mL droppers and used for glaucoma/ocular hypertension or eyelash enhancement.
  • Manufacturers In Australia: Not specified in the supplied product information.
  • Registration Status In Australia: Not specified in the supplied product information; check the TGA ARTG for current listings.
  • OTC / Rx Classification: Prescription-only (Rx) in most jurisdictions according to the provided data.

Critical Warnings & Restrictions (Safety First)

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Bimatoprost formulations can cause local and systemic effects despite limited systemic absorption.

Known hypersensitivity to bimatoprost or any excipient is an absolute contraindication.

Relative risks include current or recent intraocular inflammation such as uveitis, and aphakia or pseudophakia because of a macular oedema risk.

Immunosuppressed patients should be monitored closely due to infection risk.

Pregnancy and breastfeeding are not recommended for bimatoprost use because safety is not established.

Elderly patients usually require no dose adjustment but should be observed for systemic or ocular adverse effects.

Children are not recommended for use due to insufficient safety data.

Pharmacists and prescribers must check allergy history, eye‑surgery history, lens status and current ocular inflammation before supply.

  • Immediate Red Flags: Known allergy to bimatoprost or formulation components.
  • Immediate Red Flags: Active uveitis or recent intraocular inflammation.
  • Immediate Red Flags: Recent eye surgery or aphakia/pseudophakia.
  • Immediate Red Flags: Pregnancy or breastfeeding.

Patients should report adverse events to the Therapeutic Goods Administration via their adverse event reporting process.

Provide a patient leaflet advising to stop use and rinse the eye for severe irritation, vision changes, or other concerning symptoms and to seek urgent medical care if symptoms persist.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Bimatoprost may cause blurred vision or eye irritation shortly after administration.

Patients should avoid driving or operating heavy machinery until vision is clear after dosing.

Apply bimatoprost in the evening where possible to reduce daytime visual impairment and align with standard dosing schedules.

  • Avoid driving or using heavy machinery if vision is blurred after dosing.
  • Remove contact lenses before application and wait at least 15 minutes before reinsertion.
  • Warn about potential eyelid skin darkening and possible permanent iris pigmentation changes.

Employers with staff in safety‑sensitive roles should be informed so the employee can seek medical guidance and review workplace health and safety policies where needed.

Q&A — “Can I Drive After Taking It In Australia?”

Q: Can I drive after using bimatoprost?

A: If dosing did not cause blurred vision, significant irritation, or systemic unwellness then driving is acceptable.

A: If vision is blurred or the patient feels unwell after application, do not drive and seek medical advice.

A: Advise patients to wait until vision clears and to document this counselling in the patient notes.

Usage Basics

INN, Brand Names Available In Australia

INN: bimatoprost is the active substance.

Brand names internationally include Latisse, Lumigan and Careprost according to the product data.

In Australia, prescribers and pharmacists should confirm specific product registrations on the TGA ARTG prior to supply.

Cosmetic eyelash products such as Latisse are typically prescription-only and are not usually PBS-subsidised.

  • INN: Bimatoprost.
  • Brand: Latisse (cosmetic), Lumigan (glaucoma), Careprost (eyelash enhancement in some markets).
  • Formulation: Ophthalmic solution 0.03% w/v in 3 mL droppers commonly used for eyelash application.
  • Legal Classification (TGA‑Approved, PBS‑Listed)

    Bimatoprost products are prescription‑only in most jurisdictions according to the supplied data.

    Check the TGA ARTG to confirm whether a specific formulation and trade name are registered in Australia.

    PBS subsidy generally applies for clinical indications such as glaucoma and ocular hypertension when PBS criteria are met.

    Product Type Likely ARTG? PBS Subsidised? Prescription Required?
    Therapeutic Glaucoma Drops (eg Lumigan) Likely (check ARTG) Possibly for eligible patients Yes
    Cosmetic Eyelash Product (eg Latisse) Check ARTG No (usually private pay) Yes
    Imported Generic (eg Careprost from exporters) Varies — verify registration No May be supplied without prescription by some online sellers, but this bypasses regulations

    Always confirm current TGA and PBS status before supply or subsidy claims.

    Dosing Guide

    Standard Regimens (PBS Reference Dosing)

    For glaucoma or ocular hypertension, the standard dosing is one drop of 0.03% in the affected eye(s) once daily in the evening.

    For eyelash enhancement, apply one drop of 0.03% to an applicator and stroke along the upper eyelid margin once nightly.

    Do not apply to the lower lash line for cosmetic use.

    Consistent timing maximises efficacy for pressure control and cosmetic outcomes.

    Initial eyelash changes often appear by eight weeks with full effect by 12–16 weeks and continued use is required to maintain results.

    • Use the applicator only once and discard it if intended as single‑use.
    • Avoid spreading product to unintended skin to limit unwanted hair growth.
    • Keep regular follow-up for IOP checks when used for glaucoma.

    Adjustments For Comorbidities

    No routine dose adjustments are usually required for elderly patients, but monitor for adverse ocular or systemic effects.

    Children are not recommended for use due to lack of safety data.

    There are no formal liver or kidney impairment guidelines; use caution and consider specialist oversight for severe organ dysfunction.

    Avoid starting bimatoprost in patients with active ocular inflammation or recent intraocular surgery until an ophthalmologist reviews the case.

    • Seek specialist review for uveitis or recent intraocular surgery.
    • Consult ophthalmology for aphakia or pseudophakia due to macular oedema risk.
    • Use caution in immunosuppressed patients and document clear informed consent for off‑label cosmetic uses.

    Q&A — “What If I Miss A Dose?”

    Q: What should I do if I miss a dose?

    A: Apply as soon as remembered unless it is close to the next scheduled dose; do not double up.

    A: For cosmetic nightly use, skip that night and resume the next evening.

    A: For glaucoma therapy, keep scheduled IOP monitoring appointments and inform the prescriber if several doses are missed.

    Interaction Chart

    Food And Drinks (Alcohol, Coffee, Australian Diet Context)

    Topical bimatoprost has minimal clinically relevant interactions with food or drink due to low systemic absorption.

    There are no known interactions with alcohol or caffeine at ordinary consumption levels from the product data.

    Advise patients that excessive alcohol may worsen ocular dryness or redness and to report any systemic medications to the prescriber.

    • Monitor eye dryness with high alcohol intake.
    • Avoid applying product with heavy eye cosmetics in place.
    • Encourage reporting of all medicines and supplements during counselling.

    Common Drug Conflicts

    Systemic drug interactions are uncommon given limited systemic exposure to topical bimatoprost.

    Avoid combining multiple topical prostaglandin analogues for eyelids unless managed by an ophthalmologist due to no added benefit and potential for additive side effects.

    Coordinate glaucoma regimens with the treating ophthalmologist when combining bimatoprost with other topical glaucoma agents.

    Drug Class Interaction / Consideration Action
    Topical Prostaglandin Analogues Little added benefit; possible additive side effects Review with ophthalmologist; avoid unnecessary duplication
    Topical Beta‑Blockers (eg timolol) Often used together for glaucoma management Coordinate dosing and monitor IOP and tolerability
    Agents Increasing Ocular Inflammation May raise risk of uveitis or worsen ocular surface Exercise caution; seek specialist advice if needed

    User Reports & Trends (Australian Patient Feedback)

    Australian patient feedback collected from reviews and pharmacy consultations commonly mentions visible eyelash growth with nightly cosmetic use.

    Frequent adverse reports include conjunctival redness and eyelid darkening.

    Concerns about eye colour change are reported, and while rare this can be permanent.

    Price sensitivity is common, and consumers compare private prescriptions, online imports and major chains.

    • Pros: Noticeable eyelash length and thickness reported by many users.
    • Cons: Very common redness, occasional irritation, and some reports of skin darkening.
    • Concern: Reports of permanent iris colour change in some users.
    • Access: Many search for cheaper import options, which can carry safety risks.
    • Advice: Encourage purchase through regulated pharmacies and documented prescriptions.

    Access & Purchase Options (Australia)

    National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

    Prescription bimatoprost products are typically supplied through community pharmacies, including major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart.

    Cosmetic eyelash products usually require a private prescription and are not PBS-subsidised.

    • Confirm the prescription before dispensing.
    • Check the ARTG listing for the specific product when possible.
    • Compare prices across chains and verify product authenticity.

    Online Pharmacies And Telehealth E‑Prescriptions

    Telehealth e‑prescriptions are commonly used in Australia for drops and ointments and can be presented to community pharmacies.

    Pharmacists should verify the prescriber identity and ARTG product codes when supplied by e‑prescription.

    Online importation of Careprost or other generics from overseas is offered by some sellers without prescription; this may present legal and quality risks.

    • Steps For Safe Online Purchase: verify prescriber, check ARTG or supplier documentation, inspect batch numbers and product labelling on receipt.
    • Do not assume imported products match Australian registration or quality checks.

    In our online pharmacy, latisse is available without a prescription, with discreet delivery to Australia in 9-21 days.

    Mechanism & Pharmacology

    Simplified Explanation

    Bimatoprost is a prostaglandin analogue that lowers intraocular pressure by increasing aqueous humour outflow via the uveoscleral pathway.

    For eyelash growth, bimatoprost prolongs the anagen growth phase and increases hair bulb activity, producing longer, darker and thicker lashes over several weeks.

  • Prostaglandin Analogue: A class that alters ocular fluid dynamics.
  • Anagen Phase: The active growth phase of hair follicles.
  • IOP: Intraocular pressure, the therapeutic target in glaucoma.
  • Clinical Terms (For Prescribers And Pharmacists)

    ATC code: S01EE03 designates bimatoprost in ophthalmological prostaglandin analogues.

    Typical commercial formulation referenced in product data is 0.03% w/v in 3 mL droppers.

    Long‑term tissue changes reported include iris pigmentation increases and local skin hyperpigmentation around the eyelid.

    For cosmetic use consider baseline photography for documentation and patient records.

    Indications & Off‑Label Uses

    Approved Indications By TGA

    Internationally bimatoprost is used for glaucoma and ocular hypertension clinically and as a marketed cosmetic for eyelash hypotrichosis (Latisse in some regions).

    Confirm specific TGA ARTG approvals for each trade name and formulation before prescribing or supplying in Australia.

    PBS subsidy is generally directed to therapeutic glaucoma indications when PBS authority criteria are met.

    Off‑Label Uses In Australian Clinical Practice

    Topical bimatoprost for eyelash enhancement is used off‑label in many settings and requires informed consent.

    Counselling must include risks such as permanent iris colour change, eyelid skin darkening and ocular irritation.

    • Documentation Checklist: informed consent, baseline ocular examination, scheduled follow-up and a photo record where possible.
    • Ensure patients understand continued use is needed to maintain cosmetic effects and that some changes may be long‑lasting.

    Key Clinical Findings (Australia & International Studies 2022–2026)

    Prostaglandin analogues, including bimatoprost, provide sustained reductions in intraocular pressure for glaucoma management.

    Bimatoprost 0.03% demonstrates reliable eyelash growth with onset around eight weeks and maximal effect by 12–16 weeks.

    Safety signals include very common conjunctival hyperaemia and occasional blurred vision.

    Rare but significant findings include increased iris pigmentation which can be permanent.

    • Monitoring Parameters: IOP checks, ocular surface status and enquiring about visual symptoms at follow-up visits.
    • Report any serious or unexpected adverse events to the TGA adverse event reporting process.

    Alternatives Matrix

    PBS‑Listed Alternatives Comparison Table

    Agent Indications Typical Dosing Side‑Effect Profile PBS Status
    Bimatoprost (Lumigan/Latisse/Careprost) Glaucoma; eyelash hypotrichosis (cosmetic) 1 drop once daily evening (glaucoma); applicator nightly (cosmetic) Conjunctival hyperaemia, eyelid/iris pigmentation Therapeutic forms may be PBS‑listed; cosmetic forms usually not
    Latanoprost (Xalatan) Glaucoma / ocular hypertension 1 drop once daily evening Similar prostaglandin class effects; possible eyelash changes and pigmentation Often PBS‑subsidised for glaucoma
    Travoprost (Travatan) Glaucoma / ocular hypertension 1 drop once daily Conjunctival redness, similar class effects May be PBS‑listed for therapeutic use
    Tafluprost (Saflutan) Glaucoma / ocular hypertension 1 drop once daily Prostaglandin‑class side effects; preservative‑free options exist Possible PBS listing for specific indications

    Pros And Cons Checklist

    • Efficacy: prostaglandin analogues are effective for IOP lowering and bimatoprost shows clear eyelash effects.
    • Side‑Effect Profile: consider iris pigmentation risk and conjunctival hyperaemia.
    • Patient Preference: discuss cosmetic goals and tolerability.
    • PBS Subsidy: therapeutic choices may be influenced by PBS listings for eligible patients.
    • Cost And Convenience: long‑term cosmetic use requires ongoing private payment and maintenance dosing.

    Common Questions (Pharmacy Consultations)

    • Q: Can I use with contact lenses? A: Remove lenses before application and wait at least 15 minutes before reinserting.
    • Q: What to do for irritation? A: Rinse eyes with water, stop use and seek medical review if severe or persistent.
    • Q: How long to see effects? A: Eyelash changes often begin around eight weeks and reach full effect by 12–16 weeks.
    • Q: Are changes permanent? A: Iris pigmentation changes may be permanent; eyelash changes reverse over time after stopping.
    • Q: What about children? A: Not recommended due to lack of safety data.

    Document counselling and refer to ophthalmology for worrying signs such as vision changes, persistent pain or new floaters.

    Price & Access Comparison

    Comparison Table — Pharmacy/Source, Typical Price Range, PBS Status, Prescription Required

    Source Typical Price Range (AUD) PBS? Prescription Required? Notes
    Chain Pharmacy (eg Chemist Warehouse) $30–$120 (varies by brand and supply) Therapeutic forms may be subsidised Yes Check ARTG and product authenticity
    Private Compounding / Specialist Supplier $50–$150 No Yes May be used when branded options unavailable
    Online Import $20–$80 No Varies (some sellers offer without Rx) Potential legal and quality risks; verify batch numbers

    Rural patients should expect possible delivery delays and should confirm authenticity and registration before ordering.

    Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

    • Check local pharmacy stock before travel to avoid gaps in chronic therapy.
    • Consider mail delivery from metropolitan pharmacies for rural patients.
    • Use telehealth for e‑prescriptions where appropriate and verify ARTG codes.
    • Store at 15–25°C and discard 4 weeks after opening to reduce contamination risk.

    Registration & Regulation

    TGA Approval

    Verify individual bimatoprost products on the TGA Australian Register of Therapeutic Goods (ARTG) before prescribing or supplying.

    Bimatoprost has global approvals such as FDA approvals for Lumigan (glaucoma) and Latisse (eyelash growth), but local ARTG entries must be checked for Australian availability.

    Record ARTG numbers on prescriptions where possible to aid traceability.

    PBS Subsidy Details

    PBS generally subsidises clinically indicated glaucoma treatments where authority criteria are met.

    Cosmetic eyelash products are not usually PBS‑subsidised and are private‑pay items.

    Prescribers should confirm PBS listing and authority rules before claiming subsidy for therapeutic use.

    Storage & Handling (Australian Climate)

    Household Storage In Australian Climate (Heat/Humidity)

    Store unopened and opened bottles at room temperature between 15–25°C.

    Protect from light and moisture and do not freeze.

    Avoid leaving product in cars or in direct sunlight during hot Australian summers.

    • Keep away from bathroom humidity where possible.
    • Discard product four weeks after opening to avoid contamination.
    • Advise patients to keep product in a cool, dry cupboard away from children.

    Cold‑Chain Handling For Pharmacies

    Most bimatoprost products do not require refrigeration but must be stored at ambient room temperature and protected from moisture.

    For imported products verify transport documentation, batch numbers and seals on receipt.

    • Verify ARTG or authorised import permit for imported stock.
    • Inspect packaging integrity and report any suspected tampering.
    • Maintain batch traceability for pharmacovigilance.

    Guidelines For Proper Use (Australian Pharmacist Counselling)

    Australian Pharmacist Counselling Style

    Confirm whether the patient is using bimatoprost for glaucoma or for cosmetic eyelash enhancement.

    Explain the correct dosing and stepwise application for the patient’s indication.

    Highlight contraindications and high‑risk features and screen for allergy, pregnancy, recent eye surgery and current inflammation.

    Discuss common side effects including very common conjunctival hyperaemia and possible eyelid or iris pigmentation changes.

    • Provide written information and document the counselling in the patient record.
    • Arrange a follow‑up plan, including IOP checks for glaucoma patients.
    • Advise to stop and seek urgent care for vision changes or severe irritation.

    Patient Advice From PBS And National Health Authorities

    Therapeutic glaucoma use may be PBS‑subsidised if the patient meets PBS authority criteria; cosmetic use is private pay.

    Encourage patients to verify product registration on the TGA ARTG and to report adverse events to the TGA.

    Refer patients to their GP or ophthalmologist for ongoing monitoring and to a pharmacist for dosing queries or supply issues.

    Delivery Across Australia

    City Region Delivery Time
    Sydney New South Wales 9-14 days
    Melbourne Victoria 9-14 days
    Brisbane Queensland 9-14 days
    Perth Western Australia 9-14 days
    Adelaide South Australia 9-14 days
    Canberra Australian Capital Territory 9-14 days
    Hobart Tasmania 9-14 days
    Gold Coast Queensland 9-14 days
    Newcastle New South Wales 14-21 days
    Wollongong New South Wales 14-21 days
    Sunshine Coast Queensland 14-21 days
    Geelong Victoria 14-21 days
    Townsville Queensland 14-21 days
    Ballarat Victoria 14-21 days

    Related products